Physiomics Awarded New Contract
Why we think this is good
The RNS announcement indicates that Physiomics has been awarded a new contract worth £47,600 to provide modelling and simulation services to support the development of a first-in-class bifunctional antibody therapy. This is a positive development as it demonstrates the company's ability to expand its client base and secure new business. The contract value is also significant when considered against the company's market cap of £1.23 million. Overall, the news is positive, but does not meet the criteria for a 'Very Good' rating as it is not a profit upgrade or a statement about trading significantly ahead of market expectations.
Key Points
- Physiomics awarded new contract worth £47,600
- Contract involves modelling and simulation services for a first-in-class bifunctional antibody therapy
- Project expected to complete within 3 months
- New client win demonstrates Physiomics' ability to expand its client base
Summary
Physiomics plc, a leading mathematical modelling, data science and biostatistics company, has been awarded a new contract with a UK client. The project will involve the application of modelling and simulation techniques to support the development of a first-in-class bifunctional antibody therapy designed to target multiple solid tumour indications. The contract is valued at £47,600 and is expected to be completed over the next three months.